A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma
- PMID: 38365528
- DOI: 10.1016/j.clml.2024.01.011
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma
Abstract
In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population.
Keywords: Axi-cel; CAR T-cell; Efficacy; Indirect treatment comparison; Non-Hodgkin's lymphoma.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Disclosures PG has received consultancy fees from AstraZeneca Pharmaceuticals, Kyowa Hakko Kirin and Secura Bio, and research funding from Kite, a Gilead Company. MLP has received consultancy fees from BMS, honoraria from BeiGene, Novartis, Sythekine, Kite, a Gilead Company, MustangBio, Vor Biopharma, Rheos, Frazier Healthcare Partners, Nectar Therapeutics, Ceramedix, Lygenesis, GSK, Da Volterra, Thymofox, Notch Therapeutics, Pluto Therapeutics, and Garuda, is a current holder of stock options in Notch Therapeutics, Pluto Therapeutics, and has served on a board or committee for BeiGene. MDR current employment at and holding stock and stock options from Kite, a Gilead company. ELO: current employment at RainCity Analytics; JO: current employment at Delta Hat; SK: current employment at RainCity Analytics. SBo has no conflicts of interest to declare. MTR has no conflicts of interest to declare. CAJ has received consultancy fees and honoraria from Kite, a Gilead Company, Novartis, BMS/Celgene, Lonza,Ispen, Epizyme, Bluebird Bio, Instil Bio, ImmPACT Bio, Daiichi Sanko, AbbVie, Humanigen, Nkarta, and Precision BioSciences, has received travel support from Novartis, Lonza, Humanigen, Celgene, and Precision BioSciences, has received research funding from Kite, a Gilead Company, and has received speakers bureau from Clinical Care Options and Axis. SSN received research support from Kite, a Gilead Company, BMS, Allogene, Precision Biosciences, Adicet Bio, and Sana Biotechnology; served as Advisory Board Member/Consultant for Kite, a Gilead Company, Merck, Sellas Life Sciences, Athenex, Allogene, Incyte, Adicet Bio, BMS, Bluebird Bio, Fosun, Kite, a Gilead Company, Sana Biotechnology, Caribou, Astellas Pharma, Morphosys, Janssen, Chimagen, ImmunoACT, Orna Therapeutics, Takeda, and Synthekine; has stock options from Longbow Immunotherapy, Inc; and has intellectual property related to cell therapy. HG has received consultancy fees and honoraria from Gilead and Roche, and honoraria from BMS and AbbVie. MN, current employment at and holding stock and stock options from Kite, a Gilead company. SBe, current employment at and holding stock and stock options from Kite, a Gilead company. AP, current employment at and holding stock and stock options from Kite, a Gilead company. JG received honoraria from Janssen, AbbVie, AtraZeneca, Amgen, BMS, Kite, a Gilead Company, and Novartis and research funding from AstraZeneca, Bristol Myers Squibb, Celgene Corporation, and Janssen.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
